argenx Q3财报：Vyvgart销售超预期但营业利润不及预期，盘前股价跌逾2%（同一财报旧闻转载，无新增事实）

Tesla slips as group sets lower annual sales goal amid SpaceX merger talk
Investing.com -- Argenx shares slipped more than 2% Thursday after the biotech’s third-quarter operating profit came in well below consensus, while sales of its main drug, Vyvgart, beat expectations.
Vyvgart sales were $1.72 billion, 6% above a company-compiled consensus and 5% above the Visible Alpha consensus. Total revenue was $1.75 billion, 6% above the Visible Alpha consensus.
Operating profit, however, came in at $486 million, 11% below that Visible Alpha consensus.
Management told the analysts it will keep expanding its operating margin in 2027, with more guidance due in early 2027.
"Argenx is committed on further margin expansion, and believes top line growth is somewhat underappreciated by consensus," UBS analysts said.
The company pointed to potential new growth opportunities, including ocular and pediatric myasthenia gravis, an autoinjector version of Vyvgart and a treatment for immune-mediated necrotizing myopathy, which they are very positive will drive revenue growth.
Argenx said it is advancing FB102 into Phase 3 in celiac disease after positive Phase 2 results. Because of the large patient population, management expects a sizable Phase 3 program, with more detail on size and timing potentially coming in early 2027. It intends to move quickly given the competitive landscape.
The company has also ended a trial in Sjögren’s disease, but said it has no conclusions yet, since full analysis of the data will take months.
"While these are largely expected/no major surprises, we think the updates are reassuring, especially considering the recent share price pullback after Sjogren’s P3 termination, where the shares are trading considerably below fundamentals in our view," UBS analysts wrote.